David F Stroncek

US Patent:

20120244133, Sep 27, 2012

Filed:

Mar 20, 2012

Appl. No.:

13/424646

Inventors:

Steven A. Rosenberg - Potomac MD, US
Mark E. Dudley - Washington DC, US
David Stroncek - Rockville MD, US
Marianna Sabatino - Rockville MD, US
Jianjian Jin - Clarksburg MD, US
Robert Somerville - Montgomery Village MD, US
John R. Wilson - New Brighton MN, US

Assignee:

Wilson Wolf Manufacturing Corporation - New Brighton MN
Human Service - Bethesda MD

International Classification:

A61K 35/14
A61P 35/00
C12N 5/078

US Classification:

424 9371, 435325, 435372

Abstract:

An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.

US Patent:

20030147776, Aug 7, 2003

Filed:

Nov 6, 2002

Appl. No.:

10/289686

Inventors:

David Stroncek - Rockville MD, US
Susan Leitman - Potomac MD, US
Herbert Cullis - Gaithersburg MD, US

International Classification:

A61M001/14
A61M037/00
A61B019/00
C02F001/44

US Classification:

422/044000, 604/006020, 604/006090, 604/006030, 210/645000, 604/403000

Abstract:

A method of reducing leukocytes in whole blood by collecting whole blood from a donor, increasing the oxygen level of the whole blood, wherein the whole blood includes RBC component and a remainder component, and filtering the RBC component to reduce the amount of leukocytes.

US Patent:

20190345444, Nov 14, 2019

Filed:

Dec 6, 2018

Appl. No.:

16/211859

Inventors:

- Bethesda MD, US
- New Brighton MN, US
David Stroncek - Rockville MD, US
Marianna Sabatino - Los Angeles CA, US
Jianjian Jin - Clarksburg MD, US
Robert Somerville - Potomac MD, US
John R. Wilson - New Brighton MN, US

International Classification:

C12N 5/078
C12N 5/0783
A61K 39/00

Abstract:

An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.

US Patent:

20170152478, Jun 1, 2017

Filed:

Dec 12, 2016

Appl. No.:

15/375289

Inventors:

- Bethesda MD, US
- New Brighton MN, US
David Stroncek - Rockville MD, US
Marianna Sabatino - Rockville MD, US
Jianjian Jin - Clarksburg MD, US
Robert Somerville - Montgomery Village MD, US
John R. Wilson - New Brighton MN, US

Assignee:

The USA, as represented by the Secretary, Department of Health and Human Service - Bethesda MD
Wilson Wolf Manufacturing Corporation - New Brighton MN

International Classification:

C12N 5/078
A61K 39/00

Abstract:

An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.